Fosravuconazole L-lysine ethanolate

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate)，Ravuconazole 的前药，是一种具有口服活性的广谱抗真菌剂。Fosravuconazole L-lysine ethanolate 可用于念珠菌病，灰指甲病和寄生虫病的研究。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2725.00

2180.00

- +
10mg

￥4200.00

3360.00

- +
25mg

￥8412.00

6730.00

- +
50mg

￥13350.00

10680.00

- +
100mg

￥20912.00

16730.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx33494
CAS: 914361-45-8
别名: 磷酸咪康唑L-赖氨酸乙醇,BMS-379224 L-lysine ethanolate; E-1224 L-lysine ethanolate
分子式: C31H40F2N7O8PS
分子量: 739.73
纯度: >98%
溶解度: DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)|Water : < 0.1 mg/mL (ultrasonic) (insoluble)
储存: Store at -20°C
库存: 现货

Background

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3].

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species[1].

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3].

[1]. Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159.
[2]. Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278.
[3]. Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18.